Longitudinal evaluation of compressor/nebulizer performance

Respiratory Care

Volumn 59, Issue 7, 2014, Pages 1053-1061

  Awad, Samah ^a,b   Williams, David K ^c   Berlinski, Ariel ^c  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

^c UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Aerosol; Breathing simulation; Compressor; Cystic fibrosis; Flow; Nebulizer; Particle size; Pressure

Indexed keywords

SALBUTAMOL; AEROSOL; BRONCHODILATING AGENT;

AEROSOL; ARTICLE; HUMAN; LONGITUDINAL STUDY; LUNG FIBROSIS; MAXIMAL EXPIRATORY FLOW; MECHANICAL CHEST COMPRESSOR; NEBULIZER; PARTICLE SIZE; SIMULATION; ADMINISTRATION AND DOSAGE; BIOLOGICAL MODEL; CYSTIC FIBROSIS; DEVICE FAILURE ANALYSIS; EQUIPMENT DESIGN; INHALATIONAL DRUG ADMINISTRATION; TIME;

ADMINISTRATION, INHALATION; AEROSOLS; ALBUTEROL; BRONCHODILATOR AGENTS; CYSTIC FIBROSIS; EQUIPMENT DESIGN; EQUIPMENT FAILURE ANALYSIS; HUMANS; MODELS, BIOLOGICAL; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; TIME FACTORS;

EID: 84928106762     PISSN: 00201324     EISSN: 19433654     Source Type: Journal    
DOI: 10.4187/respcare.02776     Document Type: Article

References (25)

1. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009; 373(9678): 1891-1904.
2. Cystic Fibrosis Foundation Patient Registry. Annual data report to the Center Directors. Bethesda, MD: Cystic Fibrosis Foundation; 2010.
3. Ratjen FA. Cystic fibrosis: pathogenesis and future treatment strategies. Respir Care 2009; 54(5): 595-605.
4. Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ Jr, Willey-Courand DB, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176(10); 957-969.
5. Mogayzel PJ Jr., Naureckas ET, Robinson KA, Mueller G, Hadjili-adis D, Hoag JB, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013; 187(7): 680-689.
6. Tobi [package insert]. Novartis Pharmaceuticals Corporation, East Hanover, NJ; 2009.
7. Heijerman H, Westerman E, Conway S, Touw D, Döring G; consensus working group. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cyst Fibros 2009; 8(5): 295-315.
8. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM. Nash ML, Ramsey BW, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994; 331 (10): 637-642.
9. Scherer T, Geller DE, Owyang L, Tservesta M, Keller M, Boden N, et al. A technical feasibility study of dornase alfa delivery with eFlow vibrating membrane nebulizers: aerosol characteristics and physicochemical stability. J Pharm Sci 2011; 100(1): 98-109.
10. Pulmozyme [package insert]. Genentech, South San Francisco, CA; 2010.
11. Donaldson SH, Bennett WD, Zeman KL. Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006; 354(3): 241-250.
12. Dolovich MB, Dhand R. Aerosol drug delivery: developments in device design and clinical use. Lancet 2011; 377(9770): 1032-1045.
13. Le Brun PP, de Boer AH, Heijerman HG, Frijlink HW. A review of the technical aspects of drug nebulization. Pharm World Sci 2000; 22(3): 75-81.
14. Bauer A, McGlynn P, Bovet LL, Mims PL, Curry LA, Hanrahan JP. Output and aerosol properties of 5 nebulizer/compressor systems with arformoterol inhalation solution. Respir Care 2009: 54(10): 1342-1347.
15. Hess D, Fisher D, Williams P, Pooler S, Kacmarek RM. Medication nebulizer performance: effects of diluent volume, nebulizer flow, and nebulizer brand. Chest 1996; 110(2): 498-505.
16. Smith EC, Denyer J, Kendrick AH. Comparison of twenty three nebulizer/compressor combinations for domiciliary use. Eur Respir J 1995; 89(3): 157-159.
17. Standaert TA, Bohn SE, Aitken ML, Ramsey B. The equivalence of compressor pressure-flow relationships with respect to jet nebulizer aerosolization characteristics. J Aerosol Med 2001; 14(1): 31-42.
18. Standaert TA, Vandevanter D, Ramsey BW, Vasiljev M, Nardella P, Gmur D, et al. The choice of compressor effects the aerosol parameters and the delivery of tobramycin from a single model nebulizer. J Aerosol Med 2000; 13(2): 147-153.
19. Reisner C, Katial RK, Bartelson BB, Buchmeir A, Rosenwasser LJ, Nelson HS. Characterization of aerosol output from various nebulizer/compressor combinations. Ann Allergy Asthma Immunol 2001; 86(5): 566-574.
20. de Boer AH, Hagedoorn P. Frijlink HW. The choice of a compressor for the aerosolisation of tobramycin (TOBI) with the PARI LC PLUS reusable nebuliser. Int J Pharm 268(1-2): 59-69, 2003.
21. Standaert TA, Morlin GL. Williams-Warren J, Joy P, Pepc MS, Weber A, Ramsey BW. Effects of repetitive use and cleaning techniques of disposable jet nebulizers on aerosol generation. Chest 1998; 114(2): 577-586.
22. Berlinski A, Hayden JB. Optimization of a procedure used to measure aerosol characteristics of nebulized solutions using a cooled next generation impactor. J Aerosol Med Pulm Drug Deliv 2010; 23(6): 397-404.
23. Bauer A, McGlynn P, Bovet LL, Mims PL, Curry LA, Hanrahan JP. The influence of breathing pattern during nebulization on the delivery of arformoterol using a breath simulator. Respir Care 2009; 54(11): 1488-1492.
24. Chavez A, McCracken A, Berlinski A. Effect of face mask static dead volume, respiratory rate and tidal volume on inhaled albuterol delivery. Pediatr Pulmonol 2010; 45(3): 224-229.
25. Barry PW, O'Callaghan C. Drug output from nebulizers is dependent on the method of measurement. Eur Respir J 1998; 12(2): 463-466.